部份中文磺达肝素钠处方资料（仅供参考）
商品名：Arixtra
英文名：Limaprost Alfadex
中文名：磺达肝素钠
生产商：葛兰素史克
アリクストラ®皮下注5mg/アリクストラ®皮下注7.5mg
药用类别名称
合成XA抑制剂
批准日期：2011年3月11日
商標名
Arixtra Injection
一般名
フォンダパリヌクスナトリウム（Fondaparinux Sodium）
化学名
Decasodium methyl O-(2-deoxy-6-O-sulfo-2-sulfoamino-α-D-glucopyranosyl)-(1→4)-O-(β-D-glucopyranosyluronic acid)- (1→4)-O-(2-deoxy-3,6-di-O-sulfo-2-sulfoamino-α-D-glucopyranosyl)-(1→4)-O-(2-O-sulfo-α-L-idopyranosyluronic acid)-(1→4)-2-deoxy-6-O-sulfo-2-sulfoamino-α-D-glucopyranoside
分子式
C31H43N3Na10O49S8
分子量
1728.08
構造式
性状：
它是一种白色粉末。
操作注意事项
确保液体的内容物不允许着色或悬浮。
适应症
继发静脉血栓栓塞患者静脉血栓栓塞的抑制
·下肢整形外科患者
·腹部手术执法患者
用法与用量
通常情况下, 成人被给予皮下注射一次, 每天2.5毫克作为冯达副钠。请注意, 对于肾功能衰竭的患者, 根据肾功能的程度, 一次减少到1.5mg1 天。
包装
皮下注射剂
5mg0.4mL:10 支注射器
7.5mg0.6mL: 10个注射器
制造和销售
制造和销售元 (进口)
葛兰素史克
注：以上中文不够完整，使用者以原处方资料为准。
完整说明附件：https://jp.gsk.com/jp/media/press-releases/2011/01-p1000682/ 
GlaxoSmithKline Inc. announced on March 11 that its anticoagulant "ARIXTRA® subcutaneous injection 5 mg" and "ARIXTRA® subcutaneous injection 7.5 mg" (generic name: fondaparinux sodium, hereinafter "ARIXTRA") Following the receipt of the drug price list, we started selling on the same day.
GlaxoSmithKline Inc. (President: Philip Foche, headquarters: Shibuya-ku, Tokyo; hereinafter referred to as GSK) announced that its anticoagulant "Arixtra® subcutaneous injection 5 mg", "Arixtra® subcutaneous injection 7.5 mg (Generic name: fondaparinux sodium, hereinafter referred to as "Arixtra") was listed on the drug price, and it began selling the same day.
"Arixtra ®" is a fully chemically synthesized Xa inhibitor that selectively inhibits Activated Factor X (Xa (ten-ae factor), which plays a central role in the blood coagulation process. "ARIXTRA® subcutaneous injection 5 mg", "ARIXTRA® subcutaneous injection 7.5 mg" was approved on January 21, 2011 as "efficacy and effect of treatment of acute pulmonary thromboembolism and acute deep vein thrombosis" from the Ministry of Health, Labor and Welfare Acquired approval. It has already been approved in 64 countries, including the United States and Europe, with similar efficacy and effect.
In addition, GSK announced "ARIXTRA® subcutaneous injection 1.5 mg" and "ARIXTRA® subcutaneous injection 2.5 mg" on June 8, 2007 "Venous thrombosis in patients undergoing lower extremity orthopedic surgery with a high risk of developing venous thromboembolism" Suppression of embolism onset "as an indication of efficacy and efficacy. In addition, as of May 20, 2008, we have acquired additional indication of "the suppression of the onset of venous thromboembolism in patients with abdominal surgery with high risk of developing venous thromboembolism".
In selling, GSK President Philip Foche states as follows.
"Arixtra ®" has become a new anticoagulant that has indications from prevention to treatment of pulmonary thromboembolism and deep vein thrombosis.Therefore in Japan, in this area of ​​drug discovery that has not appeared in new drugs for decades We are extremely pleased to be able to offer new options for treatment.This product is Xa inhibitor of fully chemically synthesized and it is a simple product of subcutaneous injection once a day.These characteristics of these products are not only patients, We expect that we can offer benefits to healthcare personnel.In Japan this disease has a lower occurrence rate than in Europe and the US It seemed to be a rare disease, but in aging and living Improvement of disease cognition and countermeasures are increasingly important as a result of changes in habits etc. GSK is committed to contributing to the advancement and development of medical care in this area through the release of "Arixtra ®" We will work on it. "
■ Product characteristics of "ARIXTRA® subcutaneous injection 5 mg" and "ARIXTRA® subcutaneous injection 7.5 mg"
It is an Xa inhibitor of total chemical synthesis.
The administration method is a subcutaneous injection once daily with a prefilled syringe.
It is not necessary to adjust the dose by monitoring.
It is a drug whose efficacy and safety have been confirmed in large-scale clinical trials in Europe and the United States, and its effectiveness and safety have been confirmed even in Japan.
Short term administration to suspected or confirmed cases of pulmonary thromboembolism and deep venous thrombosis is recommended for Grade 1A in the 8th ACCP * (United States Chest Society Association) prevention guidelines for venous thromboembolism.
* American College of Chest Physicians
Product name "ARIXTRA® subcutaneous injection 5 mg", "ARIXTRA® subcutaneous injection 7.5 mg"
Common name fondaparinux sodium
Approval Date of acquisition January 21, 2011
Release date March 11, 2011
Drug price 5 mg 0.4 mL 1 cylinder, 7.5 mg 0.6 mL 1 cylinder
Efficacy/efficacy Acute Pulmonary Thromboembolism and Treatment of Acute Deep Vein Thrombosis
Dosage/dosage Usually for adults, the following doses are administered subcutaneously once daily as fondaparinux sodium.
Weight less than 50 kg: 5 mg, body weight 50 - 100 kg: 7.5 mg, body weight more than 100 kg: 10 mg